Clinical impact of contrast-enhanced computed tomography combined with low-dose 18F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2887-2892

  Chalaye, Julia ^a   Luciani, Alain ^b   Enache, Catalina ^b   Beaussart, Pauline ^b   Lhermite, Catherine ^a   Evangelista, Eva ^a   Sasanelli, Myriam ^a   Safar, Violaine ^b   Meignan, Michel ^a   Haioun, Corinne ^b   Rahmouni, Alain ^b   Itti, Emmanuel ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Contrast enhanced CT; Low dose PET CT; Lymphoma; Patient management; Radiation exposure

Indexed keywords

ANTICOAGULANT AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; VINCRISTINE; CONTRAST MEDIUM;

ABLATION THERAPY; ADULT; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCED COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EVALUATION STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LUNG INFECTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT CARE; PET-CT SCANNER; PROSPECTIVE STUDY; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIATION RESPONSE; T CELL LYMPHOMA; AGED; CANCER STAGING; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC USE; DISEASE MANAGEMENT; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; TREATMENT OUTCOME;

ADULT; AGED; CONTRAST MEDIA; DISEASE MANAGEMENT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84907226303     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.900761     Document Type: Article

References (38)

1. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844-1854.
2. Delbeke D, Stroobants S, de Kerviler E, et al. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 2009; 14(Suppl. 2): 30-40.
3. Meignan M, Barrington S, Itti E, et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 2014;55:31-37.
4. Itti E. Optimization of PET/CT with contrast enhancement in a one-stop shop setting. Paris: Ecole de MAnagement pour les M é decins des H ô pitaux (EMAMH), Assistance Publique-H ô pitaux de Paris (AP-HP) et Ecole Nationale Sup é rieure des Mines de Paris (MINES ParisTech); 2011.
5. Cheson BD, Pfstner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
6. Cheson BD, Horning SJ, Coifer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
7. ICRP. Radiation dose to patients from radiopharmaceuticals: ICRP Publication 80 (Addendum 2 to ICRP Publication 53). New York, NY: International Commission on Radiological Protection; 1998.
8. EUR16262EN. European guidelines on quality criteria for computed tomography. In: Menzel HG, Schibilla H, Teuten D, editors. European Commission's Radiation Protection Actions; 2003. Available from: http://w3.tue.nl/fileadmin/sbd/Documenten/Leergang/BSM/European-Guidelines-Quality-Criteria-Computed-Tomography- Eur-16252.pdf
9. Coulot J, Magnier F, Chauchat P, et al. Comparison between efective dose in PET/CT and CT. Méd Nucl 2011;35:156-162.
10. Picardi M, Soricelli A, Pane F, et al. Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. Radiology 2009; 251: 574-582.
11. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006;47:1643-1648.
12. Kirienko M, Guerra L, Bolis S, et al. Contrast enhanced (ce) CT in staging and end-of-treatment evaluation in lymphoma in the FDG PET/CT era: a need or a habit? J Nucl Med 2012; 53: 563.
13. Pinilla I, Gomez-Leon N, Del Campo-Del Val L, et al. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma. Q J Nucl Med Mol Imaging 2011;55:567-575.
14. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-1260.
15. 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009; 50: 527-533.
16. Meignan M, Gallamini A, Itti E, et al. Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012; 53: 1876-1881.
17. Itti E, Meignan M, Berriolo-Riedinger A, et al. An international conf rmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and D SUVmax. Eur J Nucl Med Mol Imaging 2013;40:1312-1320.
18. Elstrom RL, Leonard JP, Coleman M, et al. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 2008;19:1770-1773.
19. Muzahir S, Graham M. Follow-up of lymphoma with FDG PET-CT: no added advantage of contrast CT. J Nucl Med 2012; 53: 1367.
20. Moreiras-Plaza M, Albo C, Ares C. efficacy and safety of femoral vascular access for peripheral blood stem cell (PBSC) collection. Bone Marrow Transplant 2004;33:347-350.
21. Adorno G, Zinno F, Bruno A, et al. Femoral catheters: safety and efficacy in peripheral blood stem cell collection. Int J Artif Organs 1999;22:710-712.
22. Lekovic D, Miljic P, Mihaljevic B. Increased risk ofivenous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Tromb Res 2010;126:477-480.
23. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284.
24. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004;363:345-351.
25. Tubiana M, Feinendegen LE, Yang C, et al. The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology 2009; 251: 13-22.
26. Raanani P, Shasha Y, Perry C, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 2006;17:117-122.
27. Deak Z, Grimm JM, Treitl M, et al. Filtered back projection, adaptive statistical iterative reconstruction, and a model-based iterative reconstruction in abdominal CT: an experimental clinical study. Radiology 2013;266:197-206.
28. Rhee CM, Bhan I, Alexander EK, et al. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med 2012;172:153-159.
29. Buck AK, Herrmann K, Stargardt T, et al. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med 2010;51:401-412.
30. Cerci JJ, Trindade E, Pracchia LF, et al. Cost Effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconf rmed complete remission or partial remission after first-line therapy. J Clin Oncol 2010; 28: 1415-1421.
31. Vera P, Ouvrier MJ, Hapdey S, et al. Does chemotherapy Influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging 2007; 34: 1943-1952.
32. Beyer T, Rosenbaum S, Veit P, et al. Respiration artifacts in whole-body (18)F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. Eur J Nucl Med Mol Imaging 2005;32:1429-1439.
33. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008; 35: 2320-2333.
34. 18 F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging 2006;33:1025-1031.
35. Yeoh KW, Mikhaeel NG. Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy? Int J Radiat Oncol Biol Phys 2013;85:14-20.
36. Buchbender C, Heusner TA, Lauenstein TC, et al. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med 2012; 53: 1244-1252.
37. Lin C, Luciani A, Itti E, et al. Whole-body dif usion-weighted magnetic resonance imaging with apparent dif usion coef cient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010; 20: 2027-2038.
38. Lin C, Itti E, Luciani A, et al. Whole-body dif usion-weighted imaging with apparent dif usion coef cient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol 2011;46:341-349.